Alzheimer’s imaging pact
This article was originally published in The Gray Sheet
Executive Summary
Drug-diagnostic giant Bayer Schering licenses an Alzheimer's-detecting positron emission tomography agent from Philadelphia molecular imaging firm Avid Radiopharmaceuticals. The deal, announced June 19, results from a 2005 option agreement between the two companies for AV1/ZK and related fluorine-based compounds, which target amyloid plaques in the brain...
You may also be interested in...
The Alzheimer's Divide
Issues of clinical trial design are at the forefront in Alzheimer's drug development. Researchers and investors are weighing the impact of late-stage failures, even as significant unknowns remain about disease mechanism and the correlation of biochemical markers and clinical effects. A fundamental question hangs over AD drug development, which is unique in many respects: in deciding how to move from Phase II into Phase III, what can you know and how can you know it?
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.